Atirmociclib - Pfizer
Alternative Names: PF-07220060Latest Information Update: 28 Dec 2025
At a glance
- Originator Pfizer
- Class Amines; Antineoplastics; Benzimidazoles; Cyclic ethers; Halogenated hydrocarbons; Propanols; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III HER2 negative breast cancer
- Phase II Breast cancer; Solid tumours
- Phase I Prostate cancer
Most Recent Events
- 28 Dec 2025 No recent reports of development identified for phase-I development in Prostate-cancer in USA
- 18 Nov 2025 Pfizer completes a phase I trial for Healthy participant in USA (PO) (NCT07130097)
- 28 Oct 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA